Arthritis Gene Therapy Trial Resumes After Patient Death Investigated

Medical News Today: "The manufacturer of an experimental gene therapy drug for inflammatory arthritis said yesterday, Monday 26th November, that the US Food and Drug Administration (FDA) has allowed the phase I/II trial of the drug to resume following an investigation into the death of a patient."